참고문헌
- Ansbro MR, Shukla S, Ambudkar SV, et al (2013). Screening compounds with a novel high-throughput ABCB1-mediated efflux assay identifies drugs with known therapeutic targets at risk for multidrug resistance interference. PLoS One, 8, 60334. https://doi.org/10.1371/journal.pone.0060334
- Avan A, Crea F, Paolicchi E, et al (2012). Molecular mechanisms involved in the synergistic interaction of the EZH2 inhibitor 3-deazaneplanocin A with gemcitabine in pancreatic cancer cells. Mol Cancer Ther, 11, 1735-46. https://doi.org/10.1158/1535-7163.MCT-12-0037
- Behrens C, Solis LM, Lin H, et al (2013). EZH2 protein expression associates with the early pathogenesis, tumor progression, and prognosis of non-small cell lung carcinoma.Clin Cancer Res, 19, 6556-65. https://doi.org/10.1158/1078-0432.CCR-12-3946
- Choi JH, Song YS, Yoon JS, et al (2010). Enhancer of zeste homolog 2 expression is associated with tumor cell proliferation and metastasis in gastric cancer. APMIS, 118, 196-202. https://doi.org/10.1111/j.1600-0463.2009.02579.x
- Fujii S, Ochiai A (2008). Enhancer of zeste homolog 2 downregulates E-cadherin by mediating histone H3 methylation in gastric cancer cells. Cancer Sci, 99, 738-46. https://doi.org/10.1111/j.1349-7006.2008.00743.x
- Gadgeel SM (2013). New targets in non-small cell lung cancer.Curr Oncol Rep, 15, 411-23. https://doi.org/10.1007/s11912-013-0326-4
- Garapaty-Rao S, Nasveschuk C, Gagnon A, et al (2013).Identification of EZH2 and EZH1 small molecule inhibitors with selective impact on diffuse large B cell lymphoma cell growth. Chem Biol, 20, 1329-39. https://doi.org/10.1016/j.chembiol.2013.09.013
- Hato SV, Khong A, de Vries IJ, et al (2014). Molecular pathways: the immunogenic effects of platinum-based chemotherapeutics. Clin Cancer Res, 20, 2831-7. https://doi.org/10.1158/1078-0432.CCR-13-3141
- He LJ, Cai MY, Xu GL, et al (2013). Prognostic significance of overexpression of EZH2 and H3k27me3 proteins in gastric cancer. Asian Pac J Cancer Prev, 13, 3173-8.
- Hensing T, Chawla A, Batra R, et al (2014). A personalized treatment for lung cancer: molecular pathways, targeted therapies, and genomic characterization. Adv Exp Med Biol, 799, 85-117. https://doi.org/10.1007/978-1-4614-8778-4_5
- Hu S, Yu L, Li Z, et al (2010). Overexpression of EZH2 contributes to acquired cisplatin resistance in ovarian cancer cells in vitro and in vivo. Cancer Biol Ther, 10, 788-95. https://doi.org/10.4161/cbt.10.8.12913
- Jang WJ, Park B, Jeong GS, et al (2014). SB365, Pulsatilla saponin D, suppresses the growth of gefitinib-resistant NSCLC cells with Met amplification. Oncol Rep, 32, 2612-8.
- Janjigian YY, Smit EF, Groen HJ, et al (2014). Dual inhibition of EGFR with afatinib and cetuximab in kinase inhibitor-resistant EGFR-mutant lung cancer with and without T790M mutations. Cancer Discov, 4, 1036-45. https://doi.org/10.1158/2159-8290.CD-14-0326
- Li CH, To KF, Tong JH,et al(2013).Enhancer of zeste homolog 2 silences microRNA-218 in human pancreatic ductal adenocarcinoma cells by inducing formation of heterochromatin. Gastroenterology, 144, 1086-97. https://doi.org/10.1053/j.gastro.2013.01.058
- Liu T, Hou L, Huang Y(2014).EZH2-specific microRNA-98 inhibits human ovarian cancer stem cell proliferation via regulating the pRb-E2F pathway. Tumour Biol, 35, 7239-47. https://doi.org/10.1007/s13277-014-1950-9
- Peng SC, Liao CT, Peng CH, et al (2014). MicroRNAs MiR-218, MiR-125b, and Let-7g predict prognosis in patients with oral cavity squamous cell carcinoma. PLoS One, 9, 102403. https://doi.org/10.1371/journal.pone.0102403
- Popovic R, Martinez-Garcia E, Giannopoulou EG, et al (2014).Histone methyltransferase MMSET/NSD2 alters EZH2 binding and reprograms the myeloma epigenome through global and focal changes in H3K36 and H3K27 methylation.PLoS Genet, 10, 1004566. https://doi.org/10.1371/journal.pgen.1004566
- Powell SF, Beitinjaneh A, Tessema M, et al (2013). Phase II study of topotecan and bevacizumab in advanced, refractory non--small-cell lung cancer. Clin Lung Cancer, 14, 495-501. https://doi.org/10.1016/j.cllc.2013.04.009
- Robson CN, Gnanapragasam V, Byrne RL, et al (1999).Transforming growth factor-beta1 up-regulates p15, p21 and p27 and blocks cell cycling in G1 in human prostate epithelium. J Endocrinol, 160, 257-66. https://doi.org/10.1677/joe.0.1600257
- Sherr CJ, Roberts JM(1999).CDK inhibitors: positive and negative regulators of G1-phase progression. Genes Dev, 13, 1501-12. https://doi.org/10.1101/gad.13.12.1501
- Shi J, Qu YP, Hou P (2014). Pathogenetic mechanisms in gastric cancer. World J Gastroenterol, 20, 13804-13819. https://doi.org/10.3748/wjg.v20.i38.13804
- Suzuki M, Ikeda K, Shiraishi K, et al (2014).Aberrant methylation and silencing of IRF8 expression in non-small cell lung cancer. Oncol Lett, 8, 1025-30.
- Sneeringer CJ, Scott MP, Kuntz KW, et al (2010).Coordinated activities of wild-type plus mutant EZH2 drive tumor-associated hypertrimethylation of lysine 27 on histone H3 (H3K27) in human B-cell lymphomas. Proc Natl Acad Sci U S A, 107, 20980-5. https://doi.org/10.1073/pnas.1012525107
- Tamgue O, Chai CS, Hao L, et al (2013). Triptolide inhibits histone methyltransferase EZH2 and modulates the expression of its target genes in prostate cancer cells. Asian Pac J Cancer Prev, 10, 5663-9.
- Tie J, Pan Y, Zhao L, et al (2010). MiR-218 inhibits invasion and metastasis of gastric cancer by targeting the Robo1 receptor.PLoS Genet, 6, 1000879. https://doi.org/10.1371/journal.pgen.1000879
- Uesugi A, Kozaki K, Tsuruta T, et al (2011).The tumor suppressive microRNA miR-218 targets the mTOR component Rictor and inhibits AKT phosphorylation in oral cancer. Cancer Res, 71, 5765-78. https://doi.org/10.1158/0008-5472.CAN-11-0368
- Venkataraman S, Birks DK, Balakrishnan I, et al (2013). MicroRNA 218 acts as a tumor suppressor by targeting multiple cancer phenotype-associated genes in medulloblastoma. J Biol Chem, 288, 1918-28. https://doi.org/10.1074/jbc.M112.396762
- Wadhwa R, Elimova E, Shiozaki H, et al (2014). Anti-angiogenic agent ramucirumab: meaningful or marginal? Expert Rev Anticancer Ther, 14, 367-79. https://doi.org/10.1586/14737140.2014.896207
- Yamaguchi H, Hung MC (2014). Regulation and Role of EZH2 in Cancer. Cancer Res Treat, 46, 209-22. https://doi.org/10.4143/crt.2014.46.3.209
- Zhang D, Fan D (2010). New insights into the mechanisms of gastric cancer multidrug resistance and future perspectives.Future Oncol, 6, 527-37. https://doi.org/10.2217/fon.10.21
- Zhang JY, Lin MT, Yi T, et al (2013). Apoptosis sensitization by Euphorbia factor L1 in ABCB1-mediated multidrug resistant K562/ADR cells. Molecules, 18, 12793-808. https://doi.org/10.3390/molecules181012793
- Zhang Y, Liu G, Lin C, et al (2013). Silencing the EZH2 gene by RNA interference reverses the drug resistance of human hepatic multidrug-resistant cancer cells to 5-Fu. Life Sci, 92, 896-902. https://doi.org/10.1016/j.lfs.2013.03.010
- Zheng L, Tan W, Zhang J, et al (2014). Combining trastuzumab and cetuximab combats trastuzumab-resistant gastric cancer by effective inhibition of EGFR/ErbB2 heterodimerization and signaling. Cancer Immunol Immunother, 63, 581-6. https://doi.org/10.1007/s00262-014-1541-z
- Zhu Y, Liu XJ, Yang P, et al (2014). Alkylglyceronephosphate synthase (AGPS) alters lipid signaling pathways and supports chemotherapy resistance of glioma and hepatic carcinoma cell lines. Asian Pac J Cancer Prev, 7, 3219-26.
피인용 문헌
- Pretreatment biopsy analysis of DAB2IP identifies subpopulation of high-risk prostate cancer patients with worse survival following radiation therapy vol.4, pp.12, 2015, https://doi.org/10.1002/cam4.554
- MiR-138 Acts as a Tumor Suppressor by Targeting EZH2 and Enhances Cisplatin-Induced Apoptosis in Osteosarcoma Cells vol.11, pp.3, 2016, https://doi.org/10.1371/journal.pone.0150026
- Reversing epigenetic mechanisms of drug resistance in solid tumors using targeted microRNA delivery vol.13, pp.7, 2016, https://doi.org/10.1080/17425247.2016.1178236
- Non-coding RNAs as regulators in epigenetics vol.37, pp.1, 2016, https://doi.org/10.3892/or.2016.5236
- Interference with endogenous EZH2 reverses the chemotherapy drug resistance in cervical cancer cells partly by up-regulating Dicer expression vol.37, pp.5, 2016, https://doi.org/10.1007/s13277-015-4416-9
- Therapeutic potentials of short interfering RNAs vol.101, pp.19, 2017, https://doi.org/10.1007/s00253-017-8433-z
- Targeting NEK2 attenuates glioblastoma growth and radioresistance by destabilizing histone methyltransferase EZH2 vol.127, pp.8, 2017, https://doi.org/10.1172/JCI89092
- Up-regulation of miR-146a increases the sensitivity of non-small cell lung cancer to DDP by downregulating cyclin J vol.17, pp.1, 2017, https://doi.org/10.1186/s12885-017-3132-9
- EZH2 in Cancer Progression and Potential Application in Cancer Therapy: A Friend or Foe? vol.18, pp.6, 2017, https://doi.org/10.3390/ijms18061172
- Valproic Acid Promotes Apoptosis and Cisplatin Sensitivity Through Downregulation of H19 Noncoding RNA in Ovarian A2780 Cells vol.185, pp.4, 2018, https://doi.org/10.1007/s12010-017-2684-0